Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 3/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 2/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | BRS3 | P32247 | 1/20 | 0.31 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.30 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978876 | 0.82 | IKBKB (0.33) | MAP2SYKADORA2AJAK1JAK3 | |
| SCHEMBL986288 | 0.73 | FYN (0.38) | SYKADORA2AJAK3IKBKBLRRK2 | |
| SCHEMBL986290 | 0.73 | DYRK1B (0.39) | MAP2ADORA2AIKBKB | |
| SCHEMBL979102 | 0.69 | MEN1 (0.33) | SYK | |
| SCHEMBL15153029 | 0.69 | IKBKB (0.35) | IKBKB | |
| SCHEMBL4408031 | 0.67 | CCNC (0.32) | JAK1JAK3 | |
| SCHEMBL15153040 | 0.67 | RPS6KB1 (0.34) | IKBKBLRRK2 | |
| SCHEMBL15410115 | 0.65 | SQOR (0.33) | — | |
| SCHEMBL1507145 | 0.65 | KDM4E (0.42) | JAK1JAK3IKBKB | |
| Hydrochloric Acid SCHEMBL29898842 | 0.64 | KDM4E (0.41) | JAK1JAK3IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | MAP2 480/4885HTR2B 4736/4885SYK 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.